Glenmark Pharmaceuticals Inc., USA recalls chlorproMAZINE…
Glenmark Pharmaceuticals Inc., USA recalls chlorproMAZINE Hydrochloride Tablets
- Published
- 1 Jan 2025
- Units affected
- 2 products
- Agency
- FDA
- Country
- United States
The hazard
CGMP Deviations: N-Nitroso-Desmethyl Chlorpromazine impurity (NNDCI) were found to be failing per current FDA recommended limit.
Classification: Class II — this product may cause temporary or medically reversible health problems; the chance of serious harm is remote.
What to do
Do not stop a prescribed medicine without talking to your doctor or pharmacist first. Ask them about a replacement, and return the recalled product to the pharmacy.
- Check the lot number on the box or bottle.
- Talk to your pharmacist or doctor before stopping any prescribed medicine.
- Return the product to the pharmacy for safe disposal.
Product details
chlorproMAZINE Hydrochloride Tablets, USP, 10mg, 100-count bottle, RX only, Manufactured for: Glenmark Pharmaceuticals Inc., NJ; Product of India, NDC 68462-861-01
chlorproMAZINE Hydrochloride Tablets, USP, 25 mg, 100-count bottle, RX only, Manufactured for: Glenmark Pharmaceuticals Inc., NJ; Product of India, NDC 68462-862-01
- Brand / company
- Glenmark Pharmaceuticals Inc., USA
- Codes / lots
- Lot#: 17230132, Exp 12/2024; 17230449, Exp 01/2025 | Lot#: 17230133, Exp 12/31/2024
- Distribution
- USA Nationwide
- Recall status
- Completed
Source: U.S. Food and Drug Administration, published 1 Jan 2025. CheckMyRecalls reproduces the official notice in summary; always confirm the details with the original notice.